Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

The role of genetic markers in hepatitis C virus therapy: a major step for individualized care.

McHutchison JG.

Liver Int. 2011 Jan;31 Suppl 1:29-35. doi: 10.1111/j.1478-3231.2010.02389.x. Review.

PMID:
21205135
2.

Hepatitis C virus genotype 4 therapy: progress and challenges.

Kamal SM.

Liver Int. 2011 Jan;31 Suppl 1:45-52. doi: 10.1111/j.1478-3231.2010.02385.x. Review.

PMID:
21205137
3.

IL28B and the control of hepatitis C virus infection.

Balagopal A, Thomas DL, Thio CL.

Gastroenterology. 2010 Dec;139(6):1865-76. doi: 10.1053/j.gastro.2010.10.004. Epub 2010 Oct 13. Review.

4.

IL28B polymorphisms and chronic hepatitis C.

Chevaliez S, Hézode C.

Gastroenterol Clin Biol. 2010 Nov;34(11):587-9. doi: 10.1016/j.gcb.2010.06.008. Review.

5.

Genomic variation-guided management in chronic hepatitis C.

Hsu CS, Kao JH.

Expert Rev Gastroenterol Hepatol. 2012 Aug;6(4):497-506. doi: 10.1586/egh.12.24. Review.

PMID:
22928901
6.

Hepatitis C pharmacogenetics: state of the art in 2010.

Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, Shianna KV, Tanaka Y, Thomas DL, Booth DR, Goldstein DB; Pharmacogenetics and Hepatitis C Meeting Participants.

Hepatology. 2011 Jan;53(1):336-45. doi: 10.1002/hep.24052. Review.

PMID:
21254181
7.

Optimal therapy in genotype 1 patients.

Farnik H, Mihm U, Zeuzem S.

Liver Int. 2009 Jan;29 Suppl 1:23-30. doi: 10.1111/j.1478-3231.2008.01969.x. Review.

PMID:
19207963
8.

The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C.

Bellanti F, Vendemiale G, Altomare E, Serviddio G.

Clin Dev Immunol. 2012;2012:849373. doi: 10.1155/2012/849373. Epub 2012 Aug 27. Review.

9.

The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients.

Nelson DR.

Liver Int. 2011 Jan;31 Suppl 1:53-7. doi: 10.1111/j.1478-3231.2010.02391.x. Review.

PMID:
21205138
10.

Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients.

Mangia A.

Liver Int. 2011 Jan;31(1):36-41. doi: 10.1111/j.1478-3231.2010.02357.x. Epub 2010 Oct 12. Review.

PMID:
21040409
11.

Viral and host factors associated with outcomes of hepatitis C virus infection (Review).

Yan Z, Wang Y.

Mol Med Rep. 2017 May;15(5):2909-2924. doi: 10.3892/mmr.2017.6351. Epub 2017 Mar 22. Review.

PMID:
28339063
12.

[Genome-wide association studies].

Grimm D, Blum HE, Thimme R.

Dtsch Med Wochenschr. 2011 Jan;136(3):95-8. doi: 10.1055/s-0030-1269446. Epub 2011 Jan 11. Review. German.

PMID:
21225557
13.

Impact of host and virus genome variability on HCV replication and response to interferon.

Schweitzer CJ, Liang TJ.

Curr Opin Virol. 2013 Oct;3(5):501-7. doi: 10.1016/j.coviro.2013.06.005. Epub 2013 Jul 6. Review.

14.

Innate and adaptive genetic pathways in HCV infection.

Buchanan R, Hydes T, Khakoo SI.

Tissue Antigens. 2015 Apr;85(4):231-40. doi: 10.1111/tan.12540. Epub 2015 Feb 24. Review.

PMID:
25708172
15.

Host genetic variants in the pathogenesis of hepatitis C.

Rau M, Baur K, Geier A.

Viruses. 2012 Dec;4(12):3281-302. Review.

16.

[Host cholesterol biosynthesis as a potential target for anti-hepatitis C virus strategies].

Saito K, Fukasawa M.

Seikagaku. 2016 Jun;88(3):411-5. Review. Japanese. No abstract available.

PMID:
27483962
17.

Personalized medicine and the clinical laboratory.

Pinho JR, Sitnik R, Mangueira CL.

Einstein (Sao Paulo). 2014 Sep;12(3):366-73. Review. English, Portuguese.

Supplemental Content

Support Center